OptimaCure

Company Overview

Snapshot

Founded in August 2013, OptimaCure operated with 1–10 employees. The company ceased operations in January 2019.

Business overview

OptimaCure specializes in providing personalized treatment solutions for cancer patients by repurposing existing cancer drugs. The company's core technology involves employing multiple robust screening approaches to identify optimal drug combinations for individual cancer patients. This process aims to pinpoint patients most likely to respond positively to suggested drug treatments and to discover broader applications for repositioned cancer drugs across additional indications. OptimaCure serves the healthcare and life sciences sectors, particularly focusing on oncology, drug design, and personalized medicine.

Company Intelligence Q&A

What is OptimaCure's primary focus?

OptimaCure focuses on providing personalized treatment for cancer patients by repositioning failed cancer drugs through multiple robust screening approaches.

When was OptimaCure founded?

OptimaCure was founded in August 2013.

What is OptimaCure's operational status?

OptimaCure is currently non-active, having ceased operations in January 2019.

What industries does OptimaCure serve?

OptimaCure serves the healthcare and life sciences industries, with a focus on oncology, drug design, and personalized medicine.

What is the core technology behind OptimaCure's approach?

OptimaCure's proprietary approach combines multiple technologies, including in vivo, in vitro, and in silico methods, to enhance the understanding of drug mechanisms and reposition them for appropriate cancer patients.